MedTrace Logo

CMRA for US-guided-MWA of Liver Tumors

NCT05990257 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2023-08-15

No results posted yet for this study

Summary

Patients with liver tumors who underwent US-guided-MWA of liver tumors were enrolled. These patients were allocated into three groups based on tumor size and number: A, B, and C. Prior to the ablation procedure, Group A patients received a combination of hepatic hilar block (HHB), Transversus abdominis plane block (TAPB), and local anesthesia (LA). Patients in Group B were administered HHB in conjunction with LA, while those in Group C received TAPB and LA. Evaluative parameters included the Numerical Rating Scale (NRS) scores, consumption of morphine, incidence of complications, and factors influencing perioperative pain.

Conditions

  • Regional Anesthesia
  • Pain Control
  • Microwave Ablation
  • Liver Tumors

Interventions

PROCEDURE

HHB+TAPB+and LA

Hepatic Hilar Block (HHB), Transversus Abdominis Plane Block (TAPB), and Local Anesthesia (LA)

PROCEDURE

HHB+LA

Hepatic Hilar Block (HHB) and Local Anesthesia (LA)

PROCEDURE

TAPB+LA

Transversus Abdominis Plane Block (TAPB) and Local Anesthesia (LA)

Sponsors & Collaborators

  • Lu Wang

    lead OTHER

Principal Investigators

  • Man Lu, PHD · Sichuan Cancer Hospital and Research Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05990257 on ClinicalTrials.gov